Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
26. lappuse
... method in The United States Pharmacopeia ( USP XVIII ) , shall initi- ate recall of the subject batch when so requested ... methods ) de- scribed in paragraph ( h ) of this section . ( d ) The protocol for the in vivo bio- availability ...
... method in The United States Pharmacopeia ( USP XVIII ) , shall initi- ate recall of the subject batch when so requested ... methods ) de- scribed in paragraph ( h ) of this section . ( d ) The protocol for the in vivo bio- availability ...
30. lappuse
... methods , in addition to that described in The United States Pharmacopeia ( USP XVIII ) , developed to measure dig- oxin tablets dissolution . These two methods , the so - called " paddle - water ” and " paddle - acid " methods , are de ...
... methods , in addition to that described in The United States Pharmacopeia ( USP XVIII ) , developed to measure dig- oxin tablets dissolution . These two methods , the so - called " paddle - water ” and " paddle - acid " methods , are de ...
31. lappuse
... methods differs significantly from the apparatus de- scribed in the method in the compen- dium . The Food and Drug Administra- tion is aware that the three methods ( i.e. , USP , " paddle - water , " and " pad- dle - acid " ) show ...
... methods differs significantly from the apparatus de- scribed in the method in the compen- dium . The Food and Drug Administra- tion is aware that the three methods ( i.e. , USP , " paddle - water , " and " pad- dle - acid " ) show ...
104. lappuse
... method of syn- thesis ( or isolation ) and purification of the drug substance ; the process con- trols used during manufacture and packaging ; and such specifications and analytical methods as are necessary to assure the identity ...
... method of syn- thesis ( or isolation ) and purification of the drug substance ; the process con- trols used during manufacture and packaging ; and such specifications and analytical methods as are necessary to assure the identity ...
105. lappuse
... methods used in each study and a statement with respect to each study that it either was con- ducted in compliance with the institu- tional review board regulations in part 56 , or was not subject to the regula- tions under § 56.104 or ...
... methods used in each study and a statement with respect to each study that it either was con- ducted in compliance with the institu- tional review board regulations in part 56 , or was not subject to the regula- tions under § 56.104 or ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning